Clinical efficacy and safety of gefitinib combined with chemotherapy in treatment of advanced lung adenocarcinoma

doi:10.3877/cma.j.issn.1674-6902.2020.04.011

Abstract

Abstract:

Objective

To analyze the clinical efficacy and safety of gefitinib combined with chemotherapy in the treatment of advanced lung adenocarcinoma.

Methods

Eighty patients with advanced lung adenocarcinoma admitted to our hospital from October 2016 to June 2018 were selected for this study. The patients were divided randomly into a study group (n=38) and a control group (n=42). The study group received treatment regimen of gefitinib combined with chemotherapy, while the control group received treatment regimen of erlotinib combined with chemotherapy. The clinical efficacy, tumor size changes and incidence of adverse reactions were compared between the two groups.

Results

The total control rate of the study group was 73.7%, higher than that of the control group (50.0%), with statistical significant difference between the two groups (P<0.05). The proportion of tumor enlargement in the study group was 13.2%, lower than that of the control group (35.0%), with statistical significant difference between the two groups (P<0.05). The incidences of bone marrow depression and liver damage in the study group were 47.4% and 31.6%, respectively, which were lower than those of the control group (74.0% and 65.0%, respectively), with statistical significant difference between the two groups (P<0.05).

Conclusion

Gefitinib can improve the anticancer effect of advanced lung adenocarcinoma, reduce the occurrence of somatic discomfort, and control the proliferation of cancer cells. Therefore, gefitinib may be considered as an anticancer regimen.

Key words: Lung adenocarcinoma, Gefitinib, Combined chemotherapy, Clinical efficacy, Safety

Shen Cao, Jing Li, Qinyan Wu. Clinical efficacy and safety of gefitinib combined with chemotherapy in treatment of advanced lung adenocarcinoma[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(04): 484-487.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.04.011

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I04/484

Figures/Tables 4

References 31

1	任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2	贺雪黛，李　烜. 参苓白术散加减联合吉非替尼治疗中晚期肺腺癌21例临床研究[J]. 江苏中医药，2017, 49(4): 24-26.
3	Zhao W, Zhao H, Wang H, et al. Combined effects of pemetrexed disodium and gefitinib on radiation sensitivity in human lung adenocarcinoma cells[J]. Acta Univ Med Nanjing, 2017, 9(4): 867-870.
4	Yang L, Fan JH, Liu LL, et al. Comparison of gefitinib and platinum-based chemotherapy and only platinum-based chemotherapy to treat lung adenocarcinoma[J]. J Biol Regul Homeost Agents, 2018, 32(3): 613.
5	Urata Y, Katakami N, Morita S, et al. Randomized Phase Ⅲ Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L[J]. J Clin Oncol, 2016, 34(27): 3248-3257.
6	张洁霞，蔡　迪，李时悦，等. 非小细胞肺癌脑转移厄洛替尼和吉非替尼治疗临床比较[J]. 中华肿瘤防治杂志，2015, 22(4): 285-288.
7	Yang L, Pang R. Clinical Observation of Fuzheng Kangai Prescription Combined with Gefitinib in Treating for Advanced Lung Adenocarcinoma[J]. Acta Chinese Med, 2018, 9(5): 236-240.
8	Patel N, Wu P, Zhang H. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation[J]. Cancer Manag Res, 2017, 9: 243-248.
9	王起龙，李　敏，胡成平. 吉非替尼可能通过EGFR启动子甲基化诱导肺腺癌细胞继发性耐药[J]. 中国肺癌杂志，2015, 18(4): 193-198.
10	Kumar R, Dubashi B, Kayal S, et al. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study[J]. Indian J Cancer, 2017, 54(1): 188.
11	方　陈，周　曦，王永生，等. MiR-214对人肺腺癌细胞PC9增殖及凋亡的研究[J]. 中国肿瘤，2015, 24(10): 860-863.
12	Duan H, Peng Y, Cui H, et al. Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report：[J]. Oncotargets & Therapy, 2018, 11: 2303-2309.
13	潘　莹，黄思超，王　霞，等. NF-κB亚单位p50/p65激活促进肺腺癌H1650细胞吉非替尼耐药[J]. 南方医科大学学报，2018, 38(5): 584-590.
14	Liu Y, Jiang H, Zhou H, et al. Lentivirus-mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinoma：[J]. Oncol Lett, 2018, 15(3): 2829-2838.
15	Hsia T, Tu C, Chen H, et al. P2.03-003 Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor[J]. J Thoracic Oncol, 2017, 12(11): S2128.
16	Bjaanæs MM, Fleischer T, Halvorsen AR, et al. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.[J]. Molecul Oncol, 2016, 10(2): 330-343.
17	田　涛，傅　潇，武惠丽，等. 吉非替尼联合化疗治疗靶向治疗失败的EGFR T790M野生型晚期肺腺癌的疗效观察[J]. 现代肿瘤医学，2018, 26(22): 3582-3585.
18	朱亚宁，张　鹏，张　丹，等. 评估吉非替尼交替化疗对比化疗治疗Ⅳ期非小细胞肺癌的疗效及安全性[J]. 中国医院药学杂志，2016, 36(6): 480-484.
19	韩　伟，邝先奎，黄　堃，等. 顺铂联合培美曲塞及吉非替尼序贯化疗治疗晚期肺腺癌疗效观察[J]. 中华实用诊断与治疗杂志，2016, 30(3): 304-306.
20	罗　莉，刘玉荣. 三维适形放疗联合同步吉非替尼化疗对肺癌患者细胞因子CSF、TNF、IL-2的影响[J]. 临床和实验医学杂志，2016, 15(9): 865-868.
21	曹云堡，胡　强. 培美曲塞联合固本消癥方治疗吉非替尼或二线化疗失败后老年肺腺癌的疗效及对生活质量的影响[J]. 现代中西医结合杂志，2018, 27(27): 3029-3032.
22	江冠铭，贾　筠，谭钦全，等. 化疗交替吉非替尼治疗表皮生长因子受体突变阳性晚期非小细胞肺癌的效果[J]. 广东医学，2015, 6(11): 1757-1760.
23	徐晓鸿，陈家斌，夏银稳，等. 沙利度胺联合吉非替尼新辅助化疗对非小细胞肺癌的临床价值[J]. 昆明医科大学学报，2016, 37(1): 65-68.
24	吴辉塔，王　馨，郭艺芳，等. 晚期肺腺癌EMT和EGFR突变状态的关系及其对吉非替尼治疗疗效的影响[J]. 癌症进展，2016, 14(8): 757-760, 763.
25	胡作为，赵　霞，关江锋，等. 吉非替尼联合DC-CIK细胞治疗晚期肺腺癌的临床疗效观察[J]. 中国医师杂志，2016, 18(1): 56-59, 62.
26	娄娜娜，杨衿记，严红虹，等. 吉非替尼与紫杉醇联合卡铂治疗晚期肺腺癌患者的效果分析[J]. 中华医学杂志，2014, 94(30): 2337-2341.
27	陈文福. AC方案联合吉非替尼序贯治疗EGFR基因敏感突变的肺腺癌患者的临床疗效观察[J]. 实用癌症杂志，2018, 33(10): 1651-1654, 1658.
28	赵　峰，苗怡然，曹生亚. 吉非替尼对EGFR敏感突变肺腺癌脑转移患者的预后影响[J]. 肿瘤学杂志，2018, 24(3): 221-225.
29	程小珍，毛山山，谢宗宙，等. 吉非替尼对晚期肺癌患者PD-L1、PD-1及Th1、Th17相关指标影响研究[J]. 陕西医学杂志，2017, 46(7): 945-947.
30	徐　姝，冯继锋，林　勇. microRNA-200c预测肺腺癌患者对吉非替尼的敏感性及其机制[J]. 现代肿瘤医学，2016, 24(24): 3924-3926.
31	刘雨桃，石远凯，胡兴胜，等. 吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析[J]. 中国肺癌杂志，2014, 17(5): 401-405.

组　别		例数	男/女	年龄(岁)	ECOG评分	分期		肿瘤部位
组　别		例数	男/女	年龄(岁)	ECOG评分	ⅢB期	Ⅳ期	左上肺	左下肺	右上肺	右中肺	右下肺
研究组		38	20/18	65.7±9.2	1.5±0.4	22	16	10	7	7	8	6
对照组		40	22/18	66.0±8.3	1.6±0.5	21	19	11	9	9	8	3
统计值		-	0.044	0.151	0.972	0.229		1.501
	P值	-	0.834	0.880	0.334	0.632		0.827

组　别		例数	男/女	年龄(岁)	ECOG评分	分期		肿瘤部位
组　别		例数	男/女	年龄(岁)	ECOG评分	ⅢB期	Ⅳ期	左上肺	左下肺	右上肺	右中肺	右下肺
研究组		38	20/18	65.7±9.2	1.5±0.4	22	16	10	7	7	8	6
对照组		40	22/18	66.0±8.3	1.6±0.5	21	19	11	9	9	8	3
统计值		-	0.044	0.151	0.972	0.229		1.501
	P值	-	0.834	0.880	0.334	0.632		0.827

组　别		例数	进展	稳定	部分缓解	完全缓解	总缓解率	总控制率
研究组		38	10(26.3)	8(21.1)	20(52.6)	0(0)	18(47.4)	28(73.7)
对照组		40	20(50.0)	4(10.0)	16(40.0)	0(0)	16(40.0)	20(50.0)
	χ²值	-	-	-	-	-	0.430	4.618
	P值	-	-	-	-	-	0.512	0.032

组　别		例数	进展	稳定	部分缓解	完全缓解	总缓解率	总控制率
研究组		38	10(26.3)	8(21.1)	20(52.6)	0(0)	18(47.4)	28(73.7)
对照组		40	20(50.0)	4(10.0)	16(40.0)	0(0)	16(40.0)	20(50.0)
	χ²值	-	-	-	-	-	0.430	4.618
	P值	-	-	-	-	-	0.512	0.032

组　别		例数	缩小>50(%)	缩小25～50(%)	缩小<50(%)	增大
研究组		38	0(0)	23(60.5)	10(26.3)	5(13.2)
对照组		40	0(0)	18(45.0)	8(20.0)	14(35.0)
	χ²值	-	-	1.884	0.438	5.046
	P值	-	-	0.170	0.508	0.025

Please choose a citation manager

Content to export